Myostatin: Regulation, function, and therapeutic applications

Muscle

Volumn 2, Issue , 2012, Pages 1077-1084

  Lee, Se Jin ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882925897     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-381510-1.00079-X     Document Type: Chapter

References (57)

1. McPherron A.C., Lawler A.M., Lee S.-J. Regulation of skeletal muscle mass in mice by a new TGF&-szlig; superfamily member. Nature 1997, 387:83-90.
2. McPherron A.C., Lee S.-J. Double muscling in cattle due to mutations in the myostatin gene. Proc Natl Acad Sci USA 1997, 94:12457-12461.
3. Grobet L., Martin L.J.R., Poncelet D., Pirottin D., Brouwers B., Riquet J., et al. A deletion in the bovine myostatin gene causes the double-muscled phenotype in cattle. Nature Genet 1997, 17:71-74.
4. Kambadur R., Sharma M., Smith T.L., Bass J.J. Mutations in myostatin (GDF8) in double-muscled Belgian Blue and Piedmontese cattle. Genome Res 1997, 7:910-915.
5. Grobet L., Poncelet D., Royo L.J., Brouwers B., Pirottin D., Michaux C., et al. Molecular definition of an allelic series of mutations disrupting the myostatin function and causing double-muscling in cattle. Mamm Genome 1998, 9:210-213.
6. Clop A., Marcq F., Takeda H., Pirottin D., Tordoir X., Bibe B., et al. A mutation creating a potential illegitimate microRNA target site in the myostatin gene affects muscularity in sheep. Nature Genet. 2006, 38:813-818.
7. Mosher D.S., Quignon P., Bustamante C.D., Sutter N.B., Mellersh C.S., Parker H.G., et al. A mutation in the myostatin gene increases muscle mass and enhances racing performance in heterozygote dogs. PLoS Genetics 2007, 3:779-786.
8. Schuelke M., Wagner K.R., Stolz L.E., Hübner C., Riebel T., Kömen W., et al. Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med 2004, 350:2682-2688.
9. Bogdanovich S., Krag T.O.B., Barton E.R., Morris L.D., Whittemore L.-A., Ahima R.S., et al. Functional improvement of dystrophic muscle by myostatin blockade. Nature 2002, 420:418-421.
10. Whittemore L.-A., Song K., Li X., Aghajanian J., Davies M.V., Girgenrath S., et al. Inhibition of myostatin in adult mice increases skeletal muscle mass and strength. BBRC 2003, 300:965-971.
11. Wolfman N.M., McPherron A.C., Pappano W.N., Davies M.V., Song K., Tomkinson K.N., et al. Activation of latent myostatin by the BMP-1/tolloid family of metalloproteinases. Proc Natl Acad Sci USA 2003, 100:15842-15846.
12. Lee S.-J., Reed A., Davies M., Girgenrath S., Goad M., Tomkinson K., et al. Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc Natl Acad Sci USA 2005, 102:18117-18122.
13. LeBrasseur N.K., Schelhorn T.M., Bernardo B.L., Cosgrove P.G., Loria P.M., Brown T.A. Myostatin inhibition enhances the effects of exercise on performance and metabolic outcomes in aged mice. J Gerontol A Biol Sci Med Sci 2009, 64:940-948.
14. Zhang L., Rajan V., Lin E., Hu Z., Han H.Q., Zhou X., et al. Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease. FASEB J 2011, 25:1653-1663.
15. Anderson S.B., Goldberg A.L., Whitman M. Identification of a novel pool of extracellular pro-myostatin in skeletal muscle. J Biol Chem 2008, 283:7027-7035.
16. Lee S.-J., McPherron A.C. Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci USA 2001, 98:9306-9311.
17. Thies R.S., Chen T., Davies M.V., Tomkinson K.N., Pearson A.A., Shakey Q.A., et al. GDF-8 propeptide binds to GDF-8 and antagonizes biological activity by inhibiting GDF-8 receptor binding. Growth Factors 2001, 18:251-259.
18. Zimmers T.A., Davies M.V., Koniaris L.G., Haynes P., Esquela A.F., Tomkinson K.N., et al. Induction of cachexia in mice by systemically administered myostatin. Science 2002, 296:1486-1488.
19. Hill J.J., Davies M.V., Pearson A.A., Wang J.H., Hewick R.M., Wolfman N.M., et al. The myostatin propeptide and the follistatin-related gene are inhibitory binding proteins of myostatin in normal serum. J Biol Chem 2002, 277:40735-40741.
20. Lee S.-J. Genetic analysis of the role of proteolysis in the activation of latent myostatin. PLoS One 2008, 3:e1628.
21. Robertson D.M., Klein R., de Vos F.L., McLachlan R.I., Wettenhall R.E., Hearn M.T., et al. The isolation of polypeptides with FSH suppressing activity from bovine follicular fluid which are structurally different to inhibin. Biochem Biophys Res Commun 1987, 149:744-749.
22. Ueno N., Ling N., Ying S.Y., Esch F., Shimasaki S., Guillemin R. Isolation and partial characterization of follistatin: a single-chain Mr 35,000 monomeric protein that inhibits the release of follicle-stimulating hormone. Proc Natl Acad Sci USA 1987, 84:8282-8286.
23. Nakamura T., Takio K., Eto Y., Shibai H., Titani K., Sugino H. Activin-binding protein from rat ovary is follistatin. Science 1990, 247:836-838.
24. Gamer L.W., Wolfman N.M., Celeste A.J., Hattersley G., Hewick R., Rosen V. A novel BMP expressed in developing mouse limb, spinal cord, and tail bud is a potent mesoderm inducer in Xenopus embryos. Dev Biol 1999, 208:222-232.
25. Lee S.-J., Lee Y.-S., Zimmers T., Soleimani A., Matzuk M.M., Tsuchida K., et al. Regulation of muscle mass by follistatin and activins. Mol Endocrinol 2010, 24:1998-2008.
26. Lee S.-J. Quadrupling muscle mass in mice by targeting TGF&-szlig; signaling pathways. PLoS One 2007, 2:e789.
27. Mukherjee A., Sidis Y., Mahan A., Raher M.J., Xia Y., Rosen E.D., et al. FSTL3 deletion reveals roles for TGF&-szlig; family ligands in glucose and fat homeostasis in adults. Proc Natl Acad Sci USA 2007, 104:1348-1353.
28. Hill J.J., Qiu Y., Hewick R.M., Wolfman N.M. Regulation of myostatin in vivo by growth and differentiation factor-associated serum protein-1: a novel protein with protease inhibitor and follistatin domains. Mol Endocrinol 2003, 17:1144-1154.
29. Kondás K., Szláma G., Trexler M., Patthy L. Both WFIKKN1 and WFIKKN2 have high affinity for growth and differentiation factors 8 and 11. J Biol Chem 2008, 283:23677-23684.
30. Li Y., Li J., Zhu J., Sun B., Branca M., Tang Y., et al. Decorin gene transfer promotes muscle cell differentiation and muscle regeneration. Mol Ther 2007, 15:1616-1622.
31. Rebbapragada A., Benchabane H., Wrana J., Celeste A.J., Attisano L. Myostatin signals through a transforming growth factor ß-like signaling pathway to block adipogenesis. Mol Cell Biol 2003, 23:7230-7242.
32. Trendelenburg A.U., Meyer A., Rohner D., Boyle J., Hatakeyama S., Glass D.J. Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size. Am J Physiol Cell Physiol 2009, 296:C1258-C1270.
33. Iezzi S., Di Padova M., Serra C., Caretti G., Simone C., Maklan E., et al. Deacetylase inhibitors increase muscle cell size by promoting myoblast recruitment and fusion through induction of follistatin. Dev Cell 2004, 6:673-684.
34. Minetti G.C., Colussi C., Adami R., Serra C., Mozetta C., Parente V., et al. Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors. Nat Med 2006, 12:1147-1150.
35. Girgenrath S., Song K., Whittemore L.-A. Loss of myostatin expression alters fiber-type distribution and expression of myosin heavy chain isoforms in slow- and fast-type skeletal muscle. Muscle Nerve 2005, 31:34-40.
36. Amthor H., Macharia R., Navarrete R., Schuelke M., Brown S.C., Otto A., et al. Lack of myostatin results in excessive muscle growth but impaired force generation. Proc Natl Acad Sci USA 2007, 104:1835-1840.
37. Elashry M.I., Otto A., Matsakas A., El-Morsy S.E., Patel K. Morphology and myofiber compostion of skeletal musculature of the forelimb in young and aged wild type and myostatin null mice. Rejuvenation Res 2009, 12:269-281.
38. McPherron A.C., Huynh T.V., Lee S.-J. Redundancy of myostatin and growth/differentiation factor 11. BMC Dev Biol 2009, 9:24-32.
39. Foster K., Graham I.R., Otto A., Foster H., Trollet C., Yaworsky P.J., et al. Adeno-associated virus-8-mediated intravenous transfer of myostatin propeptide leads to systemic functional improvements of slow but not fast muscle. Rejuvenation Res 2009, 12:85-94.
40. Matsakas A., Foster K., Otto A., Macharia R., Elashry M.I., Feist S., et al. Molecular, cellular and physiological investigation of myostatin propeptide-mediated muscle growth in adult mice. Neuromuscul Disord 2009, 19:489-499.
41. Cadena S.M., Tomkinson K.N., Monnell T.E., Spaits M.E., Kumar R., Underwood K.W., et al. Administration of a soluble activin tpe IIB receptor promotes skeletal muscle growth independent of fiber type. J Appl Physiol 2010, 109:635-642.
42. Lee S.-J. Extracellular regulation of myostatin: a molecular rheostat for muscle mass. Immunol Endocr Metabol Agents Med Chem 2010, 10:183-194.
43. Wagner K.R. Clinical applications of myostatin inhibitors for neuromuscular diseases. Immunol Endocr Metabol Agents Med Chem 2010, 10:204-210.
44. Wagner K.R., Fleckenstein J.L., Amato A.A., Barohn R.J., Bushby K., Escolar D.M., et al. A Phase I/II trial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol 2008, 63:561-571.
45. Zhou X., Wang J.L., Lu J., Song Y., Kwak K.S., Jiao Q., et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 2010, 142:531-543.
46. Benny Klimek M.E., Aydogdu T., Link M.J., Pons M., Koniaris L.G., Zimmers T.A. Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochem Biophys Res Commun 2010, 391:1548-1554.
47. Sharma M., Kambadur R., Matthews K.G., Somers W.G., Devlin G.P., Conaglen J.V., et al. Myostatin, a transforming growth factor-beta superfamily member, is expressed in heart muscle and is upregulated in cardiomyocytes after infarct. J Cell Physiol 1999, 180:1-9.
48. Shyu K.G., Lu M.J., Wang B.W., Sun H.Y., Chang H. Myostatin expression in ventricular myocardium in a rat model of volume-overload heart failure. Eur J Clin Invest 2006, 36:713-719.
49. Lenk K., Schur R., Linke A., Erbs S., Matsumoto Y., Adams V., et al. Impact of exercise training on myostatin expression in the myocardium and skeletal muscle in a chronic heart failure model. Eur J Heart Fail 2009, 11:342-348.
50. Bish L.T., Morine K.J., Sleeper M.M., Sweeney H.L. Myostatin is upregulated following stress in an Erk-dependent manner and negatively regulates cardiomyocyte growth in culture and in a mouse model. PLoS One 2010, 5:e10230.
51. Heineke J., Auger-Messier M., Xu J., Sargent M., York A., Welle S., et al. Genetic deletion of myostatin from the heart prevents skeletal muscle atrophy in heart failure. Circulation 2010, 121:419-425.
52. Wilkinson H.A. Role of myostatin signaling in aging: applications for age related sarcopenia. Immunol Endocr Metabol Agents Med Chem 2010, 10:211-216.
53. McPherron A.C., Lee S.-J. Suppression of body fat accumulation in myostatin-deficient mice. J Clin Invest 2002, 109:595-601.
54. LeBrasseur N.K. Building muscle, browning fat and preventing obesity by inhibiting myostatin. Diabetologia 2012, 55:13-17.
55. Allen D.L., Cleary A.S., Speaker K.J., Lindsay S.F., Uyenishi J., Reed J.M., et al. Myostatin, activin receptor IIb, and follistatin-like-3 gene expression are altered in adipose tissue and skeletal muscle of obese mice. Am J Physiol Endocrinol Metab 2008, 294:E918-E927.
56. Akpan I., Goncalves M.D., Dhir R., Yin X., Pistilli E.E., Bogdanovich S., et al. The effects of a soluble activin type IIB receptor on obesity and insulin sensitivity. Int J Obes (Lond) 2009, 33:1265-1273.
57. Lee S.-J. Regulation of muscle mass by myostatin. Ann Rev Cell Dev Biol 2004, 20:61-86.